收费全文 | 512849篇 |
免费 | 44700篇 |
国内免费 | 19056篇 |
耳鼻咽喉 | 3663篇 |
儿科学 | 9730篇 |
妇产科学 | 5965篇 |
基础医学 | 83556篇 |
口腔科学 | 9315篇 |
临床医学 | 41049篇 |
内科学 | 85872篇 |
皮肤病学 | 6999篇 |
神经病学 | 34782篇 |
特种医学 | 11050篇 |
外国民族医学 | 124篇 |
外科学 | 41998篇 |
综合类 | 72592篇 |
现状与发展 | 57篇 |
一般理论 | 31篇 |
预防医学 | 27958篇 |
眼科学 | 8399篇 |
药学 | 65021篇 |
76篇 | |
中国医学 | 21213篇 |
肿瘤学 | 47155篇 |
2024年 | 799篇 |
2023年 | 7257篇 |
2022年 | 10493篇 |
2021年 | 21404篇 |
2020年 | 17462篇 |
2019年 | 17975篇 |
2018年 | 17432篇 |
2017年 | 17311篇 |
2016年 | 17454篇 |
2015年 | 19659篇 |
2014年 | 29613篇 |
2013年 | 33428篇 |
2012年 | 29142篇 |
2011年 | 33923篇 |
2010年 | 28605篇 |
2009年 | 28215篇 |
2008年 | 27274篇 |
2007年 | 26800篇 |
2006年 | 24357篇 |
2005年 | 21813篇 |
2004年 | 18612篇 |
2003年 | 16467篇 |
2002年 | 12814篇 |
2001年 | 11593篇 |
2000年 | 9631篇 |
1999年 | 8778篇 |
1998年 | 7127篇 |
1997年 | 6568篇 |
1996年 | 6027篇 |
1995年 | 5492篇 |
1994年 | 4899篇 |
1993年 | 4178篇 |
1992年 | 3593篇 |
1991年 | 3164篇 |
1990年 | 2637篇 |
1989年 | 2324篇 |
1988年 | 2148篇 |
1987年 | 1695篇 |
1986年 | 1481篇 |
1985年 | 2396篇 |
1984年 | 2522篇 |
1983年 | 1771篇 |
1982年 | 1896篇 |
1981年 | 1592篇 |
1980年 | 1367篇 |
1979年 | 1148篇 |
1978年 | 923篇 |
1977年 | 723篇 |
1976年 | 764篇 |
1975年 | 589篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
The common marmoset (Callithrix jacchus) is a useful experimental animal to evaluate the pharmacokinetics of drug candidates. Cytochrome P450 (P450) 2B enzyme in marmoset livers has been identified; however, only limited information on the enzymatic properties and distribution has been available.
Marmoset P450 2B6 amino acids showed high sequence identities (>86%) with those of primates including humans and cynomolgus monkeys. Phylogenetic analysis using amino acid sequences indicated that marmoset P450 2B6 was closer to human and cynomolgus monkey P450 2B6 than to P450 2B orthologs of other species, including pigs, dogs, rabbits and rodents.
Quantitative polymerase chain reaction analysis using specific primers showed P450 2B6 mRNA predominantly expressed in livers among the five marmoset tissues, similar to those of humans and cynomolgus monkeys.
Marmoset P450 2B6 heterologously expressed in Escherichia coli membranes oxidized 7-ethoxycoumarin, pentoxyresorufin, propofol and testosterone, at roughly similar rates to those of humans and/or cynomolgus monkeys. A high capacity of marmoset P450 2B6 with propofol 4-hydroxylation (at low ionic strength conditions) with a low Km value was relatively comparable to that for marmoset livers.
These results collectively indicated a high propofol 4-hydroxylation activity of P450 2B6 expressed in marmoset livers.
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献